Physician profile
William T Korman
NPI 1740298066
$8,209.61
in general payments reported to CMS, 2019-2025
55 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $342 · 2021: $176 · 2022: $981 · 2023: $1,366 · 2024: $1,886 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,676 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,675.78 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $936.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $640.95 | 2019-2025 | |
| Novo Nordisk INC | $628.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $576.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $572.31 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $505.41 | 2019-2024 | Qelbree, Tlando, Xyosted |
| Astellas Pharma US INC | $405.35 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $301.24 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $261.92 | 2019-2025 | |
| Dexcom, INC. | $229.46 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $215.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $201.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $196.96 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.49 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $192.97 | 2019-2024 | Trintellix |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $186.13 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.37 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $155.84 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $147.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $145.80 | 2019-2024 | Spravato, Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $113.50 | 2022 | |
| Daiichi Sankyo INC. | $104.15 | 2019-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $98.67 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $90.68 | 2024-2025 | Korlym |
| Stryker Corporation | $83.53 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Kowa Pharmaceuticals America, INC. | $75.40 | 2019 | |
| Arbor Pharmaceuticals, INC. | $73.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.67 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Tris Pharma INC | $71.77 | 2023-2025 | Dyanavel Xr |
| Inari Medical, INC. | $57.91 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $55.62 | 2022-2023 | Strensiq |
| Dynavax Technologies Corporation | $48.62 | 2023-2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $44.10 | 2022-2024 | Quviviq |
| Cvrx, INC. | $36.81 | 2024-2025 | Barostim Neo System |
| Optinose US, INC. | $30.48 | 2022 | |
| Ironwood Pharmaceuticals, INC | $27.24 | 2019 | |
| Edwards Lifesciences Corporation | $22.07 | 2023 | Sapien 3 Ultra Resilia |
| Ironshore Pharmaceuticals INC. | $18.43 | 2019 | |
| Si-Bone, INC. | $16.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.53 | 2024 | Nuedexta |
| Genentech USA, INC. | $15.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.41 | 2024 | Voquezna |
| Evofem Biosciences, INC. | $13.91 | 2022 | |
| Adlon Therapeutics L.P. | $13.79 | 2019 | |
| Halozyme INC | $13.51 | 2023 | |
| Xeris Pharmaceuticals, INC. | $13.51 | 2024 | Gvoke Hypopen |
| Acerus Pharmaceuticals Corporation | $13.18 | 2021 | |
| Corium, LLC | $12.83 | 2022 | |
| Antares Pharma, INC. | $12.67 | 2019 | |
| Circassia INC. | $11.92 | 2019 | |
| Boston Scientific Corporation | $11.33 | 2019 | |
| Shire North American Group INC | $11.15 | 2019 | |
| Organon LLC | $11.07 | 2025 | Nexplanon |
| Allergan, INC. | $11.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Korman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.